Patents Assigned to Bayer Pharma Aktiengesellschaft
  • COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS
    Publication number: 20210128572
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 22, 2018
    Publication date: May 6, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Antje Margret WENGNER, Gerhard SIEMEISTER
  • COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS
    Publication number: 20210128723
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (lb) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 6, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventor: Antje Margret WENGNER
  • PROLACTIN RECEPTOR ANTIBODY FOR MALE AND FEMALE PATTERN HAIR LOSS
    Publication number: 20210128728
    Abstract: The present invention is related to a formulation of the prolactin receptor antibody mat3 and its use in the treatment of male and female pattern hair loss.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 6, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Ekkehard MAY, Stefan Joachim JODL, Jörn KRÄTZSCHMAR, Christiane OTTO
  • ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM
    Publication number: 20210113504
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Macrocyclic indole derivatives
    Patent number: 10981932
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical 2019 compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 20, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Clara Christ, Kai Thede, Joachim Kuhnke, Manfred Moewes, Knut Eis, Amaury Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Philip Lienau, Ulrike Sack, Arne Scholz, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren
  • Site specific homogeneous with KSP inhibitors
    Patent number: 10973923
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
  • High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
    Patent number: 10975060
    Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Olaf Panknin, Hubertus Pietsch
  • Method and system for taking measurements in a high-throughput screening with high time resolution
    Patent number: 10969337
    Abstract: A method and a system for rapid kinetic fluorescence measurement in high-throughput screening with high time-resolution includes providing a microtiter plate having a transparent base and multiple assay wells, a dispensing system arranged above the microtiter plate for simultaneously adding liquid into multiple assay wells, an illumination system beneath the microtiter plate for illuminating the multiple assay wells simultaneously through the transparent base, a detection system for detecting electromagnetic radiation from the multiple assay wells simultaneously through the transparent base, adding 0.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 6, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Andreas Schade, Mike Küster, Klaus Ochmann, Michael Harnau, Karl-Hermann Koeching, Nils Burkhardt, Bernd Kalthof, Linn Schneider, Georg Schmidt
  • 4,5-annulated 1,2,4-triazolones
    Patent number: 10968216
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
  • Compounds, compositions and methods for cancer patient stratification and cancer treatment
    Patent number: 10966986
    Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE INC.
    Inventors: Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
  • Substituted piperidinyl tetrahydroquinolines
    Patent number: 10961221
    Abstract: The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 30, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Eva Maria Becker-Pelster, Philipp Buchgraber, Anja Buchmüller, Karen Engel, Volker Geiss, Andreas Göller, Herbert Himmel, Raimund Kast, Andreas Knorr, Dieter Lang, Gorden Redlich, Carsten Schmeck, Hanna Tinel, Frank Wunder
  • SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS
    Publication number: 20210085656
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 25, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN
  • USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES
    Publication number: 20210085664
    Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).
    Type: Application
    Filed: April 30, 2020
    Publication date: March 25, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandra RAUSCH, Stefan Joachim JODL, Jörn KRÄTZSCHMAR, Ulrich BOTHE, Nicole SCHMIDT
  • SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS
    Publication number: 20210053941
    Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.
    Type: Application
    Filed: September 1, 2020
    Publication date: February 25, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
  • Combination of PI3K-inhibitors
    Patent number: 10925880
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 23, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Martin Lange
  • Hydroxyalkyl-substituted triazole derivatives and uses thereof
    Patent number: 10927098
    Abstract: The present invention relates to novel 3-(hydroxyalkyl)-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and/or cardiovascular diseases.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 23, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Chantal Fuerstner, Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Elisabeth Pook, Heiko Schirmer, Carsten Schmeck, Pierre Wasnaire, Matthias Beat Wittwer
  • 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
    Patent number: 10927109
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 23, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximilian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • 4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS
    Publication number: 20210047297
    Abstract: The present invention covers 4-(3-amino-6-fluoro-1H-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dicarbonitrile compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 18, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Volker SCHULZE, Tobias HEINRICH, Clara CHRIST, Hans BRIEM, Adelaide Clara FARIA ALVARES DE LEMOS, Benjamin BADER, Simon HOLTON, Ulf BÖMER, Philip LIENAU, Lara Patricia KUHNKE
  • Fused imidazoles as mIDH1 inhibitors
    Patent number: 10919862
    Abstract: The present invention relates to compounds of general formula (I): in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 16, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Olaf Panknin, Ingo Hartung, Hartmut Rehwinkel, Duy Nguyen, Ludwig Zorn, Petra Helfrich, Katja Zimmermann, Roland Neuhaus
  • Combination containing SGC stimulators and mineralocorticoid receptor antagonists
    Patent number: 10918639
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 16, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Kolkhof, Peter Sandner